Laboratory of Clinical Bacteriology and Immunology, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Clin Exp Allergy. 2018 Feb;48(2):205-216. doi: 10.1111/cea.13048. Epub 2017 Dec 15.
Prophylactic administration of mesenchymal stromal cells (MSCs) derived from adipose (AD-MSC) and bone marrow tissue (BM-MSC) in ovalbumin-induced asthma hinders inflammation in a Treg-dependent manner. It is uncertain whether MSCs act through Tregs when inflammation is already established in asthma induced by a clinically relevant allergen.
Evaluate the effect of therapeutic administration of MSCs on inflammation and Treg cells in house dust mite (HDM)-induced asthma.
BM-MSCs and AD-MSCs were administered intratracheally to C57BL/6 mice 1 day after the last HDM challenge. Lung function, remodelling and parenchymal inflammation were assayed 3 or 7 days after MSCs treatment, through invasive plethysmography and histology, respectively. Bronchoalveolar lavage fluid (BALF) and mediastinal lymph nodes (mLNs) were assessed regarding the inflammatory profile by flow cytometry, ELISA and qRT-PCR. MSCs were studied regarding their potential to induce Treg cells from primed and unprimed lymphocytes in vitro.
BM-MSCs, but not AD-MSCs, reduced lung influx of eosinophils and B cells and increased IL-10 levels in HDM-challenged mice. Neither BM-MSCs nor AD-MSCs reduced lung parenchymal inflammation, airway hyperresponsiveness or mucus hypersecretion. BM-MSCs and AD-MSCs did not up-regulate Treg cell counts within the airways and mLNs, but BM-MSCs decreased the pro-inflammatory profile of alveolar macrophages. Co-culture of BM-MSCs and AD-MSCs with allergen-stimulated lymphocytes reduced Treg cell counts in a cell-to-cell contact-independent manner, although co-culture of both MSCs with unprimed lymphocytes up-regulated Treg cell counts.
MSCs therapeutically administered exert anti-inflammatory effects in the airway of HDM-challenged mice, but do not ameliorate lung function or remodelling. Although MSC pre-treatment can increase Treg cell numbers, it is highly unlikely that the MSCs will induce Treg cell expansion when lymphocytes are allergenically primed in an established lung inflammation.
预防性给予源自脂肪(AD-MSC)和骨髓组织(BM-MSC)的间充质基质细胞(MSCs)可通过 Treg 依赖性方式抑制卵清蛋白诱导的哮喘中的炎症。在由临床相关变应原诱导的哮喘中,炎症已经建立的情况下,MSCs 是否通过 Treg 发挥作用尚不确定。
评估 MSC 治疗性给药对屋尘螨(HDM)诱导的哮喘中炎症和 Treg 细胞的影响。
在最后一次 HDM 挑战后 1 天,通过气管内给予 BM-MSC 和 AD-MSC 至 C57BL/6 小鼠。通过侵入性测功法和组织学分别在 MSC 治疗后 3 或 7 天测定肺功能、重塑和实质炎症。通过流式细胞术、ELISA 和 qRT-PCR 评估支气管肺泡灌洗液(BALF)和纵隔淋巴结(mLN)的炎症谱。体外研究 MSC 从致敏和未致敏淋巴细胞诱导 Treg 细胞的潜力。
BM-MSC,但不是 AD-MSC,减少了 HDM challenged 小鼠肺内嗜酸性粒细胞和 B 细胞的浸润,并增加了 IL-10 水平。BM-MSC 和 AD-MSC 均未减少肺实质炎症、气道高反应性或黏液分泌过度。BM-MSC 和 AD-MSC 均未增加气道和 mLN 中的 Treg 细胞计数,但 BM-MSC 减少了肺泡巨噬细胞的促炎表型。BM-MSC 和 AD-MSC 与致敏淋巴细胞的共培养以细胞间接触非依赖性方式降低了 Treg 细胞计数,尽管两种 MSC 与未致敏淋巴细胞的共培养均增加了 Treg 细胞计数。
在 HDM challenged 小鼠的气道中,MSC 治疗性给药发挥抗炎作用,但不能改善肺功能或重塑。尽管 MSC 预处理可以增加 Treg 细胞数量,但在已建立的肺部炎症中,当淋巴细胞被抗原致敏时,MSCs 极不可能诱导 Treg 细胞扩增。